FCGR2A and systemic lupus erythematosus: A significant correlation has also been reported between the clinical responses to the therapies and the low-affinity FcγR polymorphisms in rituximab-treated patients of systemic lupus erythematosus (SLE) and Waldenstrom's macroglobulinemia, in Crohn's disease patients treated with anti-TNF-α IgG1 infliximab, and in pregnant women with fetal hemolytic disease treated with anti-RhD [12,15-17].